Taken together, these results demonstrate that patients with a lower FREM1 expression are more prone to develop to a more advanced stage than those with a higher FREM1 expression, suggesting a tight relationship of it with the clinicopathological characteristics of BC. Here, FREM1 is linked to breast cancer.